Open AccessReview—Recent Advances in Electrochemical Detection of Prostate Specific Antigen (PSA) in Clinically-Relevant Samples
Author(s) -
Sarah M. Traynor,
Richa Pandey,
Roderick MacLachlan,
Amin Hosseini,
Tohid F. Didar,
Feng Li,
Leyla Soleymani
Publication year - 2020
Publication title -
journal of the electrochemical society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.258
H-Index - 271
eISSN - 1945-7111
pISSN - 0013-4651
DOI - 10.1149/1945-7111/ab69fd
Subject(s) - prostate cancer , prostate specific antigen , biosensor , detection limit , point of care testing , cancer biomarkers , nanotechnology , medicine , computational biology , cancer , chemistry , materials science , biology , immunology , chromatography
Electrochemical biosensors hold great promise for enabling clinical analysis of biomarkers at the point-of-care. This is particularly of interest for cancer management due to the importance of early diagnostics as well as the critical need for frequent treatment monitoring. We have reviewed clinically-relevant electrochemical biosensors that have been developed over the past five years for the analysis of prostate specific antigen (PSA), a model protein target for prostate cancer management. We have critically evaluated the key performance metrics of these biosensors for clinical translation: limit-of-detection, linear range, and recovery rate in bodily fluids. These PSA electrochemical biosensors can be broadly categorized as sandwich assays, direct detection assays, and indirect detection assays. Among these, indirect detection assays deliver the lowest limit-of-detection. We have identified the development of multiplexed assays for detecting a panel of cancer biomarkers that includes a combination of protein and nucleic acids targets as a key priority for future development.